REUTERS - Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd (STAR.NS), for a possible price of $2 billion, Bloomberg reported on Monday.
Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.
A Pfizer spokeswoman said the company does not comment on market rumours or speculation.
Agila makes cancer treatments and antibiotics, Bloomberg said.
Pfizer shares were up 23 cents at $26.75 on the New York Stock Exchange. (Reporting By Caroline Humer; editing by John Wallace)
Trending On Reuters
One of India's most powerful politicians, Jayalalithaa Jayaram, was sworn in as chief minister of Tamil Nadu following a nine-month break, after a court overturned her conviction in a corruption case. Full Article
Gold demand slows as China eyes equities; lack of weddings in India weighs Full Article